1887

Journal of General Virology header logo

Volume 101, Issue 9

Generation of a neutralizing antibody against RD114-pseudotyped viral vectors Free

Abstract

The feline endogenous RD114 glycoprotein has proved to be an attractive envelope to pseudotype both retroviral and lentiviral vectors. As a surface protein, its detection on packaging cells as well as viral particles would be useful in different fields of its use. To address this, we generated a monoclonal antibody against RD114 by immunization of rats, termed 22F10. Once seroconversion was confirmed, purified 22F10 was cloned into murine Fc and characterized with a binding affinity of 10nM. The antibody was used to detect RD114 and its variant envelopes on different stable viral packaging cell lines (FLYRD18 and WinPac-RD). 22F10 was also shown to prevent the infections of different strains of RD-pseudotyped vectors but not related envelope glycoproteins by blocking cell surface receptor binding. We are the first to report the neutralization of viral particles by a monoclonal αRD114 antibody.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): detection , monoclonal antibody , neutralization and RD114
© 2020 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001309
2019-11-08
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/101/9/1008.html?itemId=/content/journal/jgv/10.1099/jgv.0.001309&mimeType=html&fmt=ahah

References

  1. Blumenthal R, Durell S, Viard M, Entry HIV, Fusion EG-mediated. Hiv entry and envelope glycoprotein-mediated fusion. J Biol Chem 2012; 287:40841–40849 [View Article][PubMed]
     [Google Scholar]
  2. Green N, Shinnick TM, Witte O, Ponticelli A, Sutcliffe JG et al. Sequence-Specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide. Proc Natl Acad Sci U S A 1981; 78:6023–6027 [View Article][PubMed]
     [Google Scholar]
  3. Sommerfelt MA, Weiss RA. Receptor interference groups of 20 retroviruses plating on human cells. Virology 1990; 176:58–69 [View Article][PubMed]
     [Google Scholar]
  4. Tailor CS, Nouri A, Zhao Y, Takeuchi Y, Kabat D. A sodium-dependent neutral-amino-acid transporter mediates infections of feline and baboon endogenous retroviruses and simian type D retroviruses. J Virol 1999; 73:4470–4474[PubMed]
     [Google Scholar]
  5. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994; 68:8001–8007[PubMed]
     [Google Scholar]
  6. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-Titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69:7430–7436[PubMed]
     [Google Scholar]
  7. Bell AJ, Fegen D, Ward M, Bank A. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors. Exp Biol Med 2010; 235:1269–1276 [View Article]
     [Google Scholar]
  8. Rasko JE, Battini JL, Gottschalk RJ, Mazo I, Miller AD. The RD114/simian type D retrovirus receptor is a neutral amino acid transporter. Proc Natl Acad Sci U S A 1999; 96:2129–2134 [View Article][PubMed]
     [Google Scholar]
  9. Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96:1206–1214[PubMed]
     [Google Scholar]
  10. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5:242–251 [View Article][PubMed]
     [Google Scholar]
  11. Goerner M, Horn PA, Peterson L, Kurre P, Storb R et al. Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood 2001; 98:2065–2070 [View Article][PubMed]
     [Google Scholar]
  12. Green BJ, Lee CS, Rasko JEJ. Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. J Gene Med 2004; 6:249–259 [View Article][PubMed]
     [Google Scholar]
  13. Sandrin V, Boson B, Salmon P, Gay W, Nègre D et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002; 100:823–832 [View Article][PubMed]
     [Google Scholar]
  14. Ikeda Y, Takeuchi Y, Martin F, Cosset F-L, Mitrophanous K et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21:569–572 [View Article][PubMed]
     [Google Scholar]
  15. Ward M, Sattler R, Grossman IR, Bell AJ, Skerrett D et al. A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. Mol Ther 2003; 8:804–812 [View Article][PubMed]
     [Google Scholar]
  16. Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther 2005; 11:452–459 [View Article][PubMed]
     [Google Scholar]
  17. Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S et al. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. Hum Gene Ther Methods 2013; 24:228–240 [View Article][PubMed]
     [Google Scholar]
  18. Sanber KS, Knight SB, Stephen SL, Bailey R, Escors D et al. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep 2015; 5:9021 [View Article][PubMed]
     [Google Scholar]
  19. Marin V, Stornaiuolo A, Piovan C, Corna S, Bossi S et al. RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope. Mol Ther Methods Clin Dev 2016; 3:16033 [View Article][PubMed]
     [Google Scholar]
  20. Okabe H, Gilden RV, Hatanaka M. Rd 114 virus-specific sequences in feline cellular RNA: detection and characterization. J Virol 1973; 12:984–994[PubMed]
     [Google Scholar]
  21. Shimode S, Nakaoka R, Shogen H, Miyazawa T. Characterization of feline ASCT1 and ASCT2 as RD-114 virus receptor. J Gen Virol 2013; 94:1608–1612 [View Article][PubMed]
     [Google Scholar]
  22. Okada M, Yoshikawa R, Shojima T, Baba K, Miyazawa T. Susceptibility and production of a feline endogenous retrovirus (RD-114 virus) in various feline cell lines. Virus Res 2011; 155:268–273 [View Article][PubMed]
     [Google Scholar]
  23. Yoshikawa R, Shimode S, Sakaguchi S, Miyazawa T. Contamination of live attenuated vaccines with an infectious feline endogenous retrovirus (RD-114 virus). Arch Virol 2014; 159:399–404 [View Article][PubMed]
     [Google Scholar]
  24. Narushima R, Horiuchi N, Usui T, Ogawa T, Takahashi T et al. Experimental infection of dogs with a feline endogenous retrovirus RD-114. Acta Vet Scand 2011; 53:3 [View Article][PubMed]
     [Google Scholar]
  25. Mandel MP, Stephenson JR, Hardy WD, Essex M. Endogenous RD-114 virus of cats: absence of antibodies to RD-114 envelope antigens in cats naturally exposed to feline leukemia virus. Infect Immun 1979; 24:282–285[PubMed]
     [Google Scholar]
  26. Shimode S, Nakagawa S, Miyazawa T. Multiple invasions of an infectious retrovirus in cat genomes. Sci Rep 2015; 5:8164 [View Article][PubMed]
     [Google Scholar]
  27. Ward M, Sattler R, Grossman IR, Bell AJ, Skerrett D et al. A stable murine-based RD114 retroviral packaging line efficiently transduces human hematopoietic cells. Mol Ther 2003; 8:804–812 [View Article][PubMed]
     [Google Scholar]
  28. Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 2002; 83:2091–2108 [View Article][PubMed]
     [Google Scholar]
  29. Pantophlet R, Burton DR. Gp120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739–769 [View Article][PubMed]
     [Google Scholar]
  30. Miyazawa T, Yoshikawa R, Golder M, Okada M, Stewart H et al. Isolation of an infectious endogenous retrovirus in a proportion of live attenuated vaccines for pets. J Virol 2010; 84:3690–3694 [View Article][PubMed]
     [Google Scholar]
  31. Büeler H, Mulligan RC. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996; 2:545–555 [View Article][PubMed]
     [Google Scholar]
  32. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP et al. A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 2000; 97:12295–12299 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001309
Loading
Generation of a neutralizing antibody against RD114-pseudotyped viral vectors
J. Gen. Virol. 101, 1008 (2020); https://doi.org/10.1099/jgv.0.001309
/content/journal/jgv/10.1099/jgv.0.001309
/content/journal/jgv/10.1099/jgv.0.001309
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error